Can Superconductivity's Davids Out-Innovate The U.S. Goliaths?

The Japanese think so and have-tried to sign up super startups who can’t attract U.S. corporations to their superwares SACRAMENTO, CALIF--"It’s too low-tech for some people," admits Ray Anderson cheerfully. "But I like the idea: using low tech to make high tech." Anderson casts a slightly apologetic glance around his company’s big workshop. A crazy quilt of clutter fills it: stacked chairs, boxes, empty Pepsi cans, silvery asbestos-lined gloves, metal shelves, wooden benches

Written byDeborah Blum
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

SACRAMENTO, CALIF--"It’s too low-tech for some people," admits Ray Anderson cheerfully. "But I like the idea: using low tech to make high tech." Anderson casts a slightly apologetic glance around his company’s big workshop. A crazy quilt of clutter fills it: stacked chairs, boxes, empty Pepsi cans, silvery asbestos-lined gloves, metal shelves, wooden benches and, of course, a bright-blue hydraulic press.

Using that big hydraulic press, his small corporation, Ceracon Inc., is making superconducting history. Ceracon is molding the new high-temperature super conducting materials into denser tougher, potentially machinable, shapes.

From there, says Anderson, it’s just a short step to products, a new superefficient magnet for, say, medical imaging devices.

One might assume that U.S. manufacturers would be flipping over the idea, after all, Anderson’s was one of the first practical methods of making the new ceramics usable. Not so. A few months ago Anderson wrote 40 U.S. companies and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies